A venture formation and investment firm focuses on identifying and developing overlooked or underutilized therapeutic assets to address critical unmet medical needs. The firm typically acquires or licenses these assets and builds new companies around them, working closely with experienced executives and strategic partners to drive development and long-term value creation. The firm prefers opportunities where assets are not already tied to established commercial or private entities, allowing the firm to play a primary role in venture creation. The firm engages with opportunities globally and, in addition to its venture studio model, also makes direct early-stage investments outside of company formation.
The firm is open to a broad range of therapeutic assets and compounds, with a particular emphasis on small molecules. The firm is disease-agnostic but has a preference for oncology. The firm has also begun to explore opportunities in digital health technologies. The firm does not invest in medical devices.
The firm does not impose strict requirements on companies or management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment